Autopsy report · NCT00510887

Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.

“Low accrual.”

The sponsor’s own words in the registry.

Life of this trial

Registered 7 months after it had already started.
Ran for about 6 years 8 months before it stopped.
14 participants enrolled.
Results were posted on the registry 7 months after it ended.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: Duke University
Sponsor type: University, hospital or other
Conditions: Lymphoma, Follicular
Interventions: Bortezomib; Rituximab; Fludarabine; Mitoxantrone; Dexamethasone
Participants: 14
Sites: 1
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.